2. Search Result
Search Result
Results for "

anti-obesity effects

" in MedChemExpress (MCE) Product Catalog:

36

阻害剤およびアゴニスト

8

ペプチド

15

天然物

製品番号 製品名 Target 研究分野 構造式
  • HY-P10138
    human GIP(3-30), amide
    1 Publications Verification

    		 Insulin Receptor Metabolic Disease
    Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects .
    human GIP(3-30), amide
  • HY-N0668
    Rubusoside
    2 Publications Verification

    		 GLUT Amylases NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
    Rubusoside
  • HY-N5011
    5,7-Dimethoxyflavone
    1 Publications Verification

    		 Cytochrome P450 Metabolic Disease Inflammation/Immunology Cancer
    5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor .
    5,7-Dimethoxyflavone
  • HY-B1890
    (±)-Catechin
    1 Publications Verification

    rel-Cianidanol; rel-Catechuic acid

    		 COX Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    (±)-Catechin (rel-Cianidanol) is the racemate of the green tea polyphenol Catechin. Catechin has anticancer activity and induces apoptosis. (±)-Catechin has two forms, (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. (-)-Catechin can effectively promote hBM-MSC adipocyte differentiation and increase adiponectin and PPARγ levels. (±)-Catechin has anti-tumor, anti-obesity, anti-diabetic, anti-cardiovascular, anti-infectious, hepatoprotective and neuroprotective effects .
    (±)-Catechin
  • HY-16278
    Pradigastat
    2 Publications Verification

    LCQ-908

    		 Acyltransferase BCRP OAT Infection Metabolic Disease
    Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
    Pradigastat
  • HY-P3291
    Dapiglutide
    1 Publications Verification

    ZP7570

    		 GCGR Metabolic Disease
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
    Dapiglutide
  • HY-P10138A
    human GIP(3-30), amide TFA
    1 Publications Verification

    		 Insulin Receptor Metabolic Disease
    Human GIP(3-30), amide TFA is the TFA salt form of human GIP(3-30), amide (HY-P10138). Human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide TFA has potential anti-obesity and anti-diabetic effects .
    human GIP(3-30), amide TFA
  • HY-P10927A
    BRP TFA

    BRINP2-related peptide TFA

    		 PKA AP-1 Metabolic Disease
    BRP (BRINP2-related peptide) TFA is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP TFA induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP TFA exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP TFA is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP TFA is applicable to obesity-related research .
    BRP TFA
  • HY-N3127
    Orobol

    		Casein Kinase PI3K VEGFR Metabolic Disease
    Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ) .
    Orobol
  • HY-126956
    Porphyra 334

    		Reactive Oxygen Species (ROS) MMP Collagen PPAR DNA/RNA Synthesis Apoptosis Caspase Metabolic Disease Inflammation/Immunology
    Porphyra 334 is a carnosine-like amino acid and a natural photoprotective agent and antioxidant. Porphyra-334 exerts its photoprotective effects by scavenging ROS, inhibiting the expression and activity of MMP-1/8, and promoting the synthesis of collagen and elastin. Porphyra 334 effectively inhibits linoleic acid oxidation induced by alkyl radicals (AAPH) and singlet oxygen. Porphyra 334 has anti-obesity potential by inhibiting the expression of PPARγ2 and C/EBPα. Porphyra 334 protects cells against UV-induced DNA damage and apoptosis by inhibiting the activation of caspase-3 .
    Porphyra 334
  • HY-105008
    Secoisolariciresinol diglucoside
    Maximum Cited Publications
    6 Publications Verification

    (S,S)-SDG; (S,S)-LGM2605

    		 Others Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects .
    Secoisolariciresinol diglucoside
  • HY-N3026
    Soyasaponin Ab
    1 Publications Verification

    		 PPAR Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Inflammation/Immunology
    Soyasaponin Ab is an orally active soyasaponin. Soyasaponin Ab inhibits PPARγ transcriptional activity. Soyasaponin Ab induces apoptosis in high concentrations. Soyasaponin Ab exerts anti-obesity, anti-oxidation, anti-inflammation, anti-aging effects. Soyasaponin Ab prevents Scopolamine (HY-N0296)-induced memory impairment .
    Soyasaponin Ab
  • HY-120327
    KY-226
    2 Publications Verification

    		 Phosphatase Neurological Disease Metabolic Disease
    KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .
    KY-226
  • HY-P10927
    BRP

    BRINP2-related peptide

    		 AP-1 PKA Metabolic Disease
    BRP is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP is applicable to obesity-related research .
    BRP
  • HY-103138
    (Rac)-WAY-161503 hydrochloride
    1 Publications Verification

    		 5-HT Receptor Neurological Disease Metabolic Disease
    (Rac)-WAY-161503 hydrochloride is a potent, selective, high affinity 5-HT2C receptor agonist with a Ki of 4 nM and an EC50 of 12 nM. (Rac)-WAY-161503 hydrochloride displays higher affinity for 5-HT2C than 5-HT2A and 5-HT2B receptors. (Rac)-WAY-161503 hydrochloride has anti-obesity and antidepressant effects .
    (Rac)-WAY-161503 hydrochloride
  • HY-N0114A
    (±)-Evodiamine
    1 Publications Verification

    		 Topoisomerase Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    (±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis .
    (±)-Evodiamine
  • HY-100277
    Mifobate
    1 Publications Verification

    SR-202

    		 PPAR Metabolic Disease
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate
  • HY-B1890R
    (±)-Catechin (Standard)

    rel-Cianidanol (Standard); rel-Catechuic acid (Standard)

    		 Reference Standards COX Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    (±)-Catechin (Standard) is the analytical standard of (±)-Catechin. This product is intended for research and analytical applications. (±)-Catechin (rel-Cianidanol) is the racemate of the green tea polyphenol Catechin. Catechin has anticancer activity and induces apoptosis. (±)-Catechin has two forms, (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. (-)-Catechin can effectively promote hBM-MSC adipocyte differentiation and increase adiponectin and PPARγ levels. (±)-Catechin has anti-tumor, anti-obesity, anti-diabetic, anti-cardiovascular, anti-infectious, hepatoprotective and neuroprotective effects .
    (±)-Catechin (Standard)
  • HY-P10397
    YHIEPV

    rALP-2, Rubisco anxiolytic-like peptide 2

    		 iGluR Neurological Disease Metabolic Disease
    YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects .
    YHIEPV
  • HY-N5011R
    5,7-Dimethoxyflavone (Standard)

    		Reference Standards Cytochrome P450 Metabolic Disease Inflammation/Immunology Cancer
    5,7-Dimethoxyflavone (Standard) is the analytical standard of 5,7-Dimethoxyflavone. This product is intended for research and analytical applications. 5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor .
    5,7-Dimethoxyflavone (Standard)
  • HY-103138A
    (Rac)-WAY-161503
    1 Publications Verification

    		 5-HT Receptor Neurological Disease Metabolic Disease
    (Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT2C receptor agonist with a Ki of 4 nM and an EC50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT2C than 5-HT2A and 5-HT2B receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects .
    (Rac)-WAY-161503
  • HY-P11320
    Davalintide

    		Amylin Receptor CGRP Receptor Metabolic Disease
    Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .
    Davalintide
  • HY-117843
    Ppc-1

    		Mitochondrial Metabolism Interleukin Related Bacterial Infection Metabolic Disease Inflammation/Immunology
    Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities .
    Ppc-1
  • HY-117167
    KB-141

    		Thyroid Hormone Receptor Cancer
    KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
    KB-141
  • HY-N0668R
    Rubusoside (Standard)

    		GLUT Amylases NF-κB Reference Standards Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
    Rubusoside (Standard)
  • HY-164809
    Desisopropyle-belumosudil

    		ROCK Metabolic Disease
    KD025m1 is a novel selective ROCK2 inhibitor. KD025m1 has good anti obesity, improved insulin sensitivity, and blood glucose control effects. KD025m1 can be used to study metabolic diseases such as diabetes and obesity .
    Desisopropyle-belumosudil
  • HY-N14021
    Petasites japonicus extract

    		DNA/RNA Synthesis Neurological Disease Inflammation/Immunology Cancer
    Petasites japonicus extract is the extract from Petasites japonicus with antioxidant, anti-inflammatory, anti-obesity, neuroprotective and anti-cancer effects. Petasites japonicus extract promotes osteoblast differentiation via up-regulation of Runx2 and Osterix in MC3T3-E1 cells .
    Petasites japonicus extract
  • HY-105008R
    Secoisolariciresinol diglucoside (Standard)

    (S,S)-SDG (Standard); (S,S)-LGM2605 (Standard)

    		 Reference Standards Others Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Secoisolariciresinol diglucoside (Standard) is the analytical standard of Secoisolariciresinol diglucoside. This product is intended for research and analytical applications. Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects[1][2].
    Secoisolariciresinol diglucoside (Standard)
  • HY-P11670
    Linvixdutide

    		GLP Receptor Metabolic Disease
    Linvixdutide is a glucagon and glucagon-like peptide 1 receptor (GLP-1R) agonist with anti-obesity effects .
    Linvixdutide
  • HY-N3716
    Dehydroglyasperin D

    		Aldose Reductase COX Metabolic Disease Inflammation/Immunology
    Dehydroglyasperin D inhibits rat and human Aldose Reductase (AR) (IC50: 62.4 μM and 176.2 μM respectively). Dehydroglyasperin D has anti-obesity, antioxidant effects. Dehydroglyasperin D shows anti-inflammatory activity by inhibiting COX-2 expression and the MLK3 signaling pathway. Dehydroglyasperin D also inhibits melanin synthesis. Dehydroglyasperin D is a prenylated flavonoid that can be isolated from Glycyrrhiza uralensi .
    Dehydroglyasperin D
  • HY-16278A
    Pradigastat sodium

    LCQ 908 sodium

    		 Acyltransferase BCRP OAT Infection Metabolic Disease
    Pradigastat sodium (LCQ 908 sodium) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
    Pradigastat sodium
  • HY-105900
    Ro 22-0654

    		Others Metabolic Disease
    Ro 22-0654 is a potent lipid synthesis inhibitor. Ro 22-0654 inhibits hepatic fatty acid synthesis and has antiobesity effects .
    Ro 22-0654
  • HY-16278R
    Pradigastat (Standard)

    LCQ-908 (Standard)

    		 Acyltransferase BCRP OAT Reference Standards Infection Metabolic Disease
    Pradigastat (Standard) is the analytical standard of Pradigastat. This product is intended for research and analytical applications. Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
    Pradigastat (Standard)
  • HY-N0114AR
    (±)-Evodiamine (Standard)

    		Topoisomerase Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    (±)-Evodiamine (Standard) is the analytical standard of (±)-Evodiamine. This product is intended for research and analytical applications. (±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis .
    (±)-Evodiamine (Standard)
  • HY-100277R
    Mifobate (Standard)

    SR-202 (Standard)

    		 Reference Standards PPAR Metabolic Disease
    Mifobate (Standard) is the analytical standard of Mifobate. This product is intended for research and analytical applications. Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate (Standard)
  • HY-12191
    A-331440

    		Histamine Receptor Metabolic Disease
    A-331440 is a potent and selective histamine H3 receptor antagonist that regulates neurotransmitter release by inhibiting presynaptic H3 receptors. In preclinical studies involving mice on a high-fat diet, A-331440 demonstrated dose-dependent effects on weight reduction and fat loss. At 5 mg/kg, it effectively decreased body weight comparable to dexfenfluramine, while at 15 mg/kg, it significantly reduced body fat and improved insulin tolerance, similar to mice on a low-fat diet. These findings suggest that A-331440 holds promise as an antiobesity agent by modulating histaminergic pathways involved in food intake and metabolic regulation .
    A-331440

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: